However, Werter et al. observed in patients with metastatic renal cell carcinoma (RCC) treated with everolimus that cyclophosphamide attenuates mTOR-mediated regulatory T-cell expansion without affecting clinical outcomes [174]. The gene discussed is MTOR; the disease is renal cell carcinoma.